The problems of diagnosis, treatment, prevention of chronic obstructive pulmonary disease remain relevant due to the increase in morbidity, disability and mortality of patients. Recently, the level of renal dysfunction in the progression of chronic obstructive pulmonary disease has increased. The purpose of research was to study the indicators of renal dysfunction in chronic obstructive pulmonary disease, depending on the severity and frequency of chronic obstructive pulmonary disease exacerbations, comorbidity, respiratory function, morphological and functional state of the myocardium to optimize the diagnosis and prognosis of chronic obstructive pulmonary disease. Material and methods. The article presents the results of examination of 81 patients in different groups of chronic obstructive pulmonary disease (BCD) with comorbidity (arterial hypertension in 49 patients, diabetes mellitus type 2 – in 16, postinfarction cardiosclerosis – in 6, diffuse cardiosclerosis – in 53, angina pectoris – in 5 patients). The external respiration function was made by using a computer spirograph. The morphological and functional state of the myocardium was studied by the standard ultrasound examination. Glomerular filtration rate was estimated by using the Cockcroft-Gault formula. The A/C ratio, microalbuminuria in the morning urine portion, and the level of C-reactive protein were also studied. The results of the studies were analyzed by methods of nonparametric statistics with an assessment of differences between groups of patients using the Mann-Whitney U-test; to assess the parameters of the relationship between indicators, the method of pair rank correlation by Spearman was used. Results and discussion. Signs of renal dysfunction, hypoxia (SpO2), systemic inflammation of low intensity C-reactive protein were found only in group D of patients with chronic obstructive pulmonary disease. In the same group, the greatest number of correlations of indicators of renal dysfunction and SpO2 with various indicators of the morphofunctional state of the myocardium according to echocardiography, the frequency of exacerbations, and comorbidity with hypertension, diffuse and postinfarction cardiosclerosis was revealed. In group B and C, no correlations of indicators of renal dysfunction with other indicators were found. In the group of patients with GFR less than 90 ml/min/1.73m2, there were correlations of the A/C ratio with the frequency of exacerbations, C-reactive protein, correlations between microalbuminuria and dyspnea, daily proteinuria, and SPPA. Conclusion. In the future, it is necessary to continue the search for early specific available biomarkers of renal dysfunction that can be used for early prescription of pleiotropic therapy, and timely initiation of nephroprotection from the standpoint of network medicine

Keywords: chronic obstructive pulmonary disease, kidney, comorbidity, network medicine

Full text: PDF (Rus) 315K

1. Gozhenko AI, Kovalevska LA, Gorbenko TM. Osoblyvosti funktsionalnogo stanu nyrok u khvorykh z khronichnym obstruktyvnym zakhvoryuvan legen [Features of the functional state of the kidneys in patients with chronic obstructive pulmonary disease]. Aktualnye problemy transportnoy medytsyny. 2014; 3(37): 61-66. [Ukrainian]
2. Barabanova EN. GOLD (2017): chto y pochemu yzmenylos v globalnoy strategyy lechenyya KhOBL [GOLD (2017): what has changed and why in the global COPD treatment strategy]. Pulmonologyya. 2017; 27(2): 274-288. [Russian] https://doi.org/10.18093/0869-0189-2017-27-2-274-282
3. Bolotova EV, Dudnykova AV. Khronycheskaya bolezn pochek u patsyentov s khronycheskoy obstruktyvnoy boleznyu lyogkykh: rol chastoty obostrenyy [Chronic kidney disease in patients with chronic obstructive pulmonary disease: the role of exacerbation frequency]. Pulmonologyya. 2016; 26(5): 578-583. [Russian] https://doi.org/10.18093/0869-0189-2016-26-5-578-583
4. Fabbian F, De Giorgi A, Manfredini F, Lamberti N, Forcellini S, Storari A, et al. Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study. Int Urol Nephrol. 2016; 48(7): 1121-1127. https://doi.org/10.1007/s11255-016-1272-5 PMid:27020445
5. Fedeli U, De Giorgi N, Ferroni E, Gallerani M, Mikhailidis DP. Lung and kidney: a dangerous liaison? A population based cohort study in COPD patients in Italy. Int J Chron Obstruct Pulmon Dis. 2017; 12: 443-450. https://doi.org/10.2147/COPD.S119390 PMid:28184156 PMCid:PMC5291454
6. Chen CY, Liao KM. Chronic obstructive pulmonary diseases associated with risk of chronic kidney disease: a nation-wide case-cohort study. Sci Rep. 2016; 6: 258-55. https://doi.org/10.1038/srep25855 PMid:27166152 PMCid:PMC4863146
7. Puzyryov VP. Geneticheskie osnovy komorbidnosti u cheloveka [Genetic basis of comorbidity in humans]. Genetika. 2015; 4: 491-495. [Russian] https://doi.org/10.7868/S0016675815040098
8. Vertkin VP. Ob ispolzovanii termina «sintropiya» v nauchnykh issledovaniyakh [On the use of the term "syntropy" in scientific research]. Nauchnoe obozrenie. Referativnyy zhurnal. 2016; 3: 81-84. [Russian]
9. Ospanova TS, Semidotskaya ZhD, Chernyakova IA. Osobennosti korrelyatsiy u patsientov s KhOZL v usloviyakh komorbidnosti kak proyavlenie sintropii [Features of correlations in patients with COPD in conditions of comorbidity as a manifestation of syntropy]. Science Review. 2018; 3(10): 32-38. [Russian]
10. Shirinskiy VS Shirinskiy IV. Komorbidnye zabolevaniya - aktualnaya problema klinicheskoy meditsiny [Comorbid diseases are an urgent problem of clinical medicine]. Sibirskiy med zhurnal. 2014; 29(1): 7-12. [Russian]
11. Vilyasov VB, Solovyova NV, Kremenitskaya SA, Kuvshinova YaV. Geneticheskaya sintropiya ili komorbidnost? Kliniko-geneticheskiy analiz rezultatov issledovaniya patsienta s monosomiey 18R [Genetic syntropy or comorbidity? Clinical and genetic analysis of the results of a study of a patient with monosomy 18P]. Sovr problemy nauki i obrazovaniya. 2017; 4. [Russian]. Available from: https: www.sciense-education.ru/ru article/view? id= 26660
12. Barabasi AL, Guhlbace N, Loscalzo J. Network Medicine: a network - based approach to human disease. Nat Rev Genet. 2011; 12(1): 56-68. https://doi.org/10.1038/nrg2918 PMid:21164525 PMCid:PMC3140052
13. Marx P, Antal P, Bolgar B, Bagdy G, Deakin B, Juhasz G. Comorbidities in the diseasome are more apparent than real: what Bayesian filtering reveals about the comorbidities of depression. PLoS Comput Biol. 2017 Jun 23; 13(6): e1005487. https://doi.org/10.1371/journal.pcbi.1005487 PMid:28644851 PMCid:PMC5507322
14. Hidalgo CA, Blumm N, Barabasi AL, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol. 2009; 5(4). https://doi.org/10.1371/journal.pcbi.1000353 PMid:19360091 PMCid:PMC2661364
15. Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, et al. COPD comorbidities network. Eur Respir J. 2015; 46(3): 640-50. https://doi.org/10.1183/09031936.00171614 PMid:26160874
16. Aysanov ZR, Chuchalin AG, Kalmanova EN. Khronicheskoe obstruktivnoe zabolevanie lyogkikh i serdechno-sosudistaya komorbidnost [Chronic obstructive pulmonary disease and cardiovascular comorbidity]. Kardiologiya. 2019; 59(85): 24-36. [Russian] https://doi.org/10.18087/cardio.2572 PMid:31526359
17. Raherison C, Ouaalaya EH, Bernady A, Casteigt J, Nocent-Eijnani C, Falque L, et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med. 2018 Jul 16; 18(1): 117. https://doi.org/10.1186/s12890-018-0684-7 PMid:30012144 PMCid:PMC6048834
18. Degtyar NI, Gerasimenko ND, Savchenko LV, Rasin MS. Sistemnoe vospalenie nizkoy intensivnosti kak obshchaya osnova obstruktivnogo zabolevaniya lyogkikh i komorbidnykh sostoyaniy [Low-intensity systemic inflammation as a common basis for obstructive pulmonary disease and comorbid conditions]. Ukr pulm zhurnal. 2016; 3: 64-68. [Russian]
19. Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et al. Clusters of comorbidities based on validation objective measurements and systemic inflammation in patients with chronic obstructive pulmonare disease. Am J Respir Crit Care Med. 2013 Apr 1; 187(7): 728-35. https://doi.org/10.1164/rccm.201209-1665OC PMid:23392440
20. Damman K, Masson S, Hillege HL, Voors AA, van Veldhuisen DJ, Rossignol P, et al. Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail. 2013 Oct; 1(5): 417-24. https://doi.org/10.1016/j.jchf.2013.05.007 PMid:24621973
21. Сelli BR, Anderson JA, Brook R, Calverley P, Cowans NJ, Crim C, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res. 2019 May 4; 6(1): e000431. https://doi.org/10.1136/bmjresp-2019-000431 PMid:31258919 PMCid:PMC6561388
22. Zakharova NB, Pastushkova LKh, Lyakh RV. Opredelenie biomarkerov povrezhdeniya pochechnoy parenkhimy v moche patsientov s khronicheskim pielonefritom metodami IFA i mass-spektrometrii [Determination of biomarkers of renal parenchyma damage in the urine of patients with chronic pyelonephritis by ELISA and mass spectrometry]. Meditsinskaya immunologiya. 2019; 21(2): 341-350. [Russian] https://doi.org/10.15789/1563-0625-2019-2-341-350
23. Smirnov AE. Sistemnyy podkhod k analizu kardiorenalnykh vzaimootnosheniy kak pervyy shag na puti k nefrologii formata R4 [A systematic approach to the analysis of cardiorenal relationships as the first step towards nephrology of the P4 format]. Nefrologiya. 2011; 15(2): 11-19. [Russian]
24. Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, et al. Conseqences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res. 2019 Jul 12; 20(1): 151. https://doi.org/10.1186/s12931-019-1107-x PMid:31299972 PMCid:PMC6626422
25. Rosenberg J. Chronic Kidney Disease in chronic obstructive pulmonary negatively impacts mortality, other patient outcomes. AJMC. 2019. Available from: https://www.ajmc.com/view/chronic-kidney-disease-in-copd-negatively-impacts-mortality-other-patient-outcomes
26. Polverino F., Laucho-Conteras NE, Petersen H, Bijol V, Sholl LM, Choi ME, et al. A pilot study linking endothelial injury in lungs and kidneys in chronic obstructive pulmonary disease. Am J Respir Crit Med. 2017; 195(11): 1464-1467. https://doi.org/10.1164/rccm.201609-1765OC PMid:28085500 PMCid:PMC5470750
27. Leonova TS, Vikhnina MV Grishina TV. Vliyanie konechnykh produktov glubokogo glikirovaniya na kletochnye protsessy [Influence of end products of deep glycation on cellular processes]. Mezhdunarodnyy nauchno-issledovatelskiy zhurnal. 2018; 12(78): 185-189. [Russian] https://doi.org/10.233670/iRJ
28. Kuzmin OB. KhBP: mekhanizmy razvitiya i progressirovaniya gipoksicheskogo glomeruloskleroza i tubulointerstitsialnogo fibroza [CKD: mechanisms of development and progression of hypoxic glomerulosclerosis and tubulointerstitial fibrosis]. Nefrologiya. 2015; 19(4): 9-16. [Russian]
29. Lisyanskaya OYu. Gipoksiya - vedushchiy faktor progressirovaniya khronicheskoy bolezni pochek [Hypoxia is a leading factor in the progression of chronic kidney disease]. Pochki. 2016; 1(15): 64-66. [Russian] https://doi.org/10.22141/2307-1257.1.15.2016.71483
30. Zoccali C., Vanholder R., Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017; 13(6): 344-58. https://doi.org/10.1038/nrneph.2017.52 PMid:28435157